HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
OTC Drugs

Mucinex Patent Ruling Breathes Life Into Watson And Perrigo ANDAs

This article was originally published in The Tan Sheet

  • News

Executive Summary

Watson Pharmaceuticals' success against Reckitt Benckiser's Mucinex patent infringement suit could clear a path for Mucinex equivalents to launch in the first half of 2011.

You may also be interested in...



In Brief

Watson prevails in Mucinex patent ruling

Reckitt Benckiser Revenue Grows 15% On OTCs, SSL Acquisition

Reckitt Benckiser reports net revenue up 15% in its latest earnings period on strong sales of OTC products and new business from the now fully integrated SSL International brands.

News In Brief

Allegra available OTC nationwide

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
OTC Drugs
Latest Headlines

Cosmetic And Personal Care Weekly Trademarks Review: 5 December

Dr. Teal’s Tucks In Some Melatonin Topical Sleep Claims After P&G Challenge, Keeps Others Awake

Unilever Squelches Dr. Squatch Comparative Claims In NAD Forum; Advertiser Can Keep Its 'Sh*t List’

Refillable Personal-Care Packaging: Experts Discuss Contamination Risks, Liability, MoCRA Compliance

See All
UsernamePublicRestriction

Register

RS133975

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By